A Randomized Phase II Study of Docetaxel +/ – ZD6474 (Zactima) in Metastatic Transitional Cell Carcinoma May 5, 2022 By Jesse Bufkin
Prospective Randomized Investigation to Evaluate incidence of headache reduction in subjects with Migraine and PFO Using the AMPLATZER PFO Occluder compared to Medical Management May 5, 2022 By Jesse Bufkin
A Phase I, Multiple Ascending Dose Study of BMS-663513, an Agonistic Anti-CD137 Monoclonal Antibody, Administered in Combination with Chemotherapy to Subjects with Recurrent Platinum Sensitive Ovarian Carcinoma May 5, 2022 By Jesse Bufkin
A Phase II/III Randomized Study of CDX-110 with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma Muliforme May 5, 2022 By Jesse Bufkin
A Phase 3, Randomized, Double-Blind, Parallel, Placebo-Controlled, Multicenter Study, with Optional Open-Label Continuation, of the Efficacy and Safety of Vanquix Auto-Injector (Diazepam Injection) for the Management of Selected, Refractory, Patients with May 5, 2022 By Jesse Bufkin
Lapatinib & Gemcitabine for Metastatic Pancreatic Cancer: A Phase II Study May 5, 2022 By Jesse Bufkin
A Phase 2a Randomized, Placebo-controlled, Double-Blind Study of VX-770 to Evaluate Safety, Pharmacokinetics, and Biomarkers of CFTR Activity in Cystic Fibrosis Subjects with Genotype G551D May 5, 2022 By Jesse Bufkin
A Multicenter Treatment Protocol for Compassionate Use of Ipilimumab (BMS-734016) Monotherapy in Subjects with Unresectable Stage III or Stage IV Melanoma May 5, 2022 By Jesse Bufkin
